Laverock Therapeutics, established in 2021 to commercialise a gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications
Laverock Therapeutics has raised €26M across 3 funding rounds from 9 investors, most recently a Grant round in Jun 2026. Based in Stevenage, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-06-01 | Grant | €2.5M | — | View deal → |
| 2025-06-30 | Seed | €7.6M | Calculus Capital,Eli lilly and company,Eos Advisory,Maven Capital Partners,Mercia Ventures,Norcliffe Capital | View deal → |
| 2023-10-02 | Seed | €16M | Calculus Capital,Eli lilly and company,EOS Ventures,Maven Capital Partners,Mercia Ventures,Tekfen Ventures+1 more | View deal → |
